Please assess the completion status of the following clinical trial:

Trial Title: S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed\* grade 1, 2, or 3 follicular B-cell non-Hodgkin lymphoma meeting the following criteria:~  * Bulky stage II or stage III or IV disease~ * Diffuse large cell component must be \< 25% of the biopsy~ * Confirmed cluster of differentiation antigen 20 (CD20) antigen-positive disease NOTE: \*Needle aspiration or cytology are not considered adequate for pathology review~* Patient must have unilateral or bilateral bone marrow aspirate and biopsy performed within 42 days~  * Positive biopsy performed \> 42 days but \< 6 months allowed~* Previously untreated disease~* Bidimensionally measurable disease~* No clinical evidence of central nervous system (CNS) involvement by lymphoma~PATIENT CHARACTERISTICS:~* Zubrod performance status 0-2~* Cardiac ejection fraction ≥ 45% by multigated acquisition scan (MUGA) or ECHO~* No significant cardiac abnormalities~* No known HIV positivity~* No requirement for continuous supplemental oxygen therapy~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer from which the patient is currently in complete remission~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 12 months after completion of maintenance therapy~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy, radiotherapy, or antibody therapy for lymphoma~* No prior solid organ transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- R-CHOP, tositumomab and rituximab (Type: EXPERIMENTAL): Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 IV Day 1 Prednisone 100 mg PO Days 1-5 Rituximab 375 mg/m2 IV Day 1 Q 21 Days x 6 Cycles~Patients are restaged by CT scan. Unlabeled tositumomab antibody 450 mg IV within 12 after Cycle 6 of CHOP. Dosimetric dose 35 mg IV after infusion of unlabeled tositumomab antibody. Unlabeled tositumomab antibody 450 mg IV 7-14 days after dosimetric dose. Therapeutic dose 35 mg IV after infusion of unlabeled tositumomab antibody.~Rituximab 375 mg/m2 IV q 3 months x 4 years beginning 1 year after registration.

Based on this trial design, predict the completion outcome and termination type (if applicable).